ClinicalTrials.gg
RecruitingNCT07472920EMPA-BDUpdated Nov 16, 2026

Empagliflozin Adjunctive Therapy in Bipolar Depression

An interventional study of Empagliflozin (EMPA) in Bipolar Disorder, Bipolar Depression and Insulin Resistance, sponsored by University of Sao Paulo. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by University of Sao Paulo · Not applicable, Interventional, and Treatment

How we know

Updated Nov 16, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Bipolar Disorder by University of Sao Paulo — 3 open to participants now, 4 under way, 1 of them phase 3. Bipolar Disorder · University of Sao Paulo.

Planned enrollment
13th of 13
20 · median 60
Started
2026
with 2 others
No phase
7 of 15
2 open now
Registered
15th of 15
by date

Among the 15 studies in Bipolar Disorder by University of Sao Paulo, this one is the 13th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2026, is one of 7 with no phase, and was the 15th registered.

Bipolar Disorder

1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

3 of the 15 studies in Bipolar Disorder by University of Sao Paulo are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Bipolar Disorder by University of Sao Paulo, or all of them as a file.
02

Study summary

Bipolar disorder is a long-term mental health condition that causes mood changes, with depressive episodes being the most frequent and disabling. Many people do not fully recover with current treatments, showing the need for new therapeutic options.

Recent research shows that insulin resistance (IR), a condition in which the body does not respond well to insulin, is common in people with bipolar disorder. It is linked to more severe mood symptoms, poorer treatment response, and higher risk of heart disease. IR may raise inflammation and affect how the brain uses energy, which can influence mood regulation.

Empagliflozin is a medicine approved for type 2 diabetes. In addition to its metabolic and heart benefits, studies suggest that it may also protect the brain and reduce inflammation, possibly helping to improve mood.

This open-label, proof-of-concept clinical trial will test how well empagliflozin works and how safe it is as an add-on treatment for people with bipolar depression and insulin resistance. A total of 20 adults with bipolar disorder type I or II, currently in a depressive episode, will take part in the study over a 12-week period.

The main goal is to see whether empagliflozin can lower depressive symptoms, measured with the Montgomery-Åsberg Depression Rating Scale (MADRS). Other measures include changes in insulin resistance and incidence of adverse events.

The study aims to explore whether improving insulin resistance can help both mood and metabolic health in people with bipolar disorder, guiding future clinical research.

Read the detailed description

This study is an open-label, single-arm, proof-of-concept clinical trial evaluating empagliflozin as an adjunctive treatment for bipolar depression in individuals with insulin resistance. Adults with bipolar disorder type I or II who are currently experiencing a depressive episode and receiving stable pharmacological treatment will receive empagliflozin for 12 weeks.

Depressive symptom severity will be assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). Insulin resistance will be evaluated using the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), and safety will be monitored through assessment of treatment-emergent adverse events throughout the study period.

03

Conditions studied

  • Bipolar Disorder
  • Bipolar Depression
  • Insulin Resistance

Keywords

  • Bipolar Disorder
  • Bipolar Depression
  • Insulin Resistance
  • Empagliflozin
  • SGLT2 Inhibitors
  • Metabolic Psychiatry
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18 to 65 years.
  2. Diagnosis of Bipolar Disorder type I or II according to criteria, confirmed by the MINI International Neuropsychiatric Interview.
  3. Montgomery-Åsberg Depression Rating Scale (MADRS) score ≥ 15 at screening.
  4. Currently receiving stable pharmacological treatment for bipolar disorder, with no medication changes (addition or withdrawal) in the past 4 weeks.
  5. Ability to provide .
  6. Insulin resistance, defined as HOMA-IR ≥ 1.8.

Exclusion criteria

Exclusion Criteria:

  1. History of to empagliflozin or any SGLT2 inhibitor.
  2. Type 1 or type 2 diabetes mellitus or ≥ 6.5% at screening.
  3. Known pancreatic disease (pancreatitis or pancreatic surgery).
  4. Chronic kidney disease ( \< 30 mL/min/1.73m²).
  5. Recurrent genital fungal infections.
  6. Pregnant or breastfeeding.
  7. Alcohol abuse or dependence within the past 12 months.
  8. YMRS score ≥ 12 (presence of manic or hypomanic symptoms).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Empagliflozin Adjunctive Therapy in Bipolar Depression

    Participants will receive empagliflozin orally once daily as an adjunct to their usual psychiatric treatment. The dose will start at 10 mg/day for the first 2 weeks and increase to 25 mg/day for the following 10 weeks, totaling a 12-week intervention period. The study will evaluate changes in depressive symptoms, insulin resistance, and metabolic parameters in adults with bipolar depression and insulin resistance. All participants will continue their standard psychiatric medications under medical supervision throughout the study.

    Drug: Empagliflozin (EMPA)

Interventions

  • DrugEmpagliflozinStudies of EmpagliflozinEmpagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor administered orally once daily. Participants will start with 10 mg/day for the first 2 weeks, followed by 25 mg/day for the next 10 weeks, completing a 12-week intervention period. The drug will be used as an adjunctive treatment to standard psychiatric therapy in adults with bipolar depression and insulin resistance. Safety and tolerability will be monitored throughout the study.

    Also known as: Jardiance

06

What researchers measure

Primary outcomes

  1. Change in depressive symptom severity (MADRS total score)

    The Montgomery-Åsberg Depression Rating Scale (MADRS) will be used to assess depressive symptom severity. The scale includes 10 clinician-rated items, with higher scores indicating more severe depression. The primary outcome is the change in total MADRS score from baseline to week 12 of treatment with empagliflozin.

    Time frame: Baseline and 12 weeks after treatment initiation

Secondary outcomes

  1. Change in insulin resistance (HOMA-IR)

    Insulin resistance will be assessed using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated from fasting glucose and insulin levels. The outcome will be the change in HOMA-IR from baseline to week 12.

    Time frame: Baseline and 12 weeks after treatment initiation

  2. Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)

    Adverse events will be recorded throughout the 12-week study period. Safety will be assessed through adverse event monitoring, clinical evaluation, and laboratory tests (including renal function and electrolytes).

    Time frame: Throughout the 12-week study period

07

Study locations

1 of 1 sites recruiting
  • Institute of Psychiatry, University of São Paulo Medical School (IPq-FMUSP)
    São Paulo, São Paulo 05403-903, Brazil
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — The individual participant data (IPD) will not be shared because this is a small, proof-of-concept, single-site study. The dataset includes sensitive clinical information that could potentially identify participants. Only aggregated and anonymized results will be shared in future scientific publications or presentations.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Aug 2027, 9 months after the start.

Of 361 non-industry interventional studies with no phase under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 9 months is below that.

Counting every sponsor, half of 363 studies reached it within 37 months; a quarter within 23 and three quarters within 58.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: start Mar 2026 → Nov 2026, primary completion Sep 2026 → Aug 2027 and completion Dec 2026 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2026
First posted
Mar 16, 2026
StartActual
Nov 12, 2026was Mar 2026
Primary completionEst.
Aug 2027was Sep 2026
CompletionEst.
Aug 2027was Dec 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 16, 2026
Sites
Institute of Psychiatry, University of São Paulo Medical School (IPq-FMUSP) is now Recruiting
Nov 16, 2026
Start date
Mar 9, 2026→Nov 12, 2026 (actual)
Nov 16, 2026
Primary completion
Sep 2026→Aug 2027
Nov 16, 2026
Study completion
Dec 2026→Aug 2027
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Not yet recruiting→Recruiting
    Institute of Psychiatry, University of São Paulo Medical School (IPq-FMUSP) is now Recruiting
    Start date Mar 9, 2026→Nov 12, 2026 (now actual)
    Primary completion Sep 2026→Aug 2027
    Study completion Dec 2026→Aug 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07472920
Responsible party
Beny Lafer (Associated professor, University of Sao Paulo) — Principal investigator
First posted
Mar 16, 2026
Start date
Nov 12, 2026
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Eliana Landivar, MD
Contact
eliana.landivar@hc.fm.usp.br
+55 11 2661 7890
Beny Lafer, MD, PhD
principal investigator · Institute of Psychiatry, University of São Paulo Medical School (IPq-FMUSP)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion